- Home
- LLY
as 05-09-2025 9:54am EST
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
| Founded: | 1876 | Country: | United States |
| Employees: | N/A | City: | INDIANAPOLIS |
| Market Cap: | 652.7B | IPO Year: | N/A |
| Target Price: | $1005.05 | AVG Volume (30 days): | 4.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 19 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 12.29 | EPS Growth: | 80.99 |
| 52 Week Low/High: | $677.09 - $972.53 | Next Earning Date: | 05-01-2025 |
| Revenue: | $49,003,200,000 | Revenue Growth: | 36.38% |
| Revenue Growth (this year): | 33.5% | Revenue Growth (next year): | 19.38% |
Stock Insider Trading Activity of Eli Lilly and Company (LLY)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| LILLY ENDOWMENT INC | LLY | 10% Owner | Mar 3 '25 | Sell | $928.71 | 220,000 | $204,326,150.89 | 96,218,150 | |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Feb 25 '25 | Sell | $905.96 | 225,000 | $203,190,794.31 | 96,218,150 | |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Feb 24 '25 | Sell | $59,386.22 | 60,432 | $1,648,756,039.51 | 96,218,150 | |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Feb 21 '25 | Sell | $885.59 | 99,452 | $87,786,505.01 | 96,218,150 | |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Feb 20 '25 | Sell | $878.84 | 14,685 | $12,893,352.83 | 96,218,150 | |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Feb 19 '25 | Sell | $878.96 | 9,985 | $8,771,285.36 | 96,218,150 | |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Feb 13 '25 | Sell | $880.55 | 35,446 | $31,175,396.35 | 96,218,150 |
Latest Eli Lilly and Company News
LLY Breaking Stock News: Dive into LLY Ticker-Specific Updates for Smart Investing
MT Newswires
2 hours ago
Eli Lilly to Invest $250 Million in Collaboration With Purdue University
Bloomberg
2 hours ago
Wall Street Brings the Bitcoin-Versus-Gold Clash to ETF Masses
PR Newswire
2 hours ago
Lilly plans to expand Purdue University collaboration with up to a $250 million investment to accelerate pharmaceutical innovation
Argus Research
3 hours ago
Market Digest: CTSH, HIG, LLY, MO, SHEL, SYK, VRSK, KHC
Argus Research
3 hours ago
Analyst Report: Lilly(Eli) & Co
Motley Fool
4 hours ago
4 No-Brainer Stocks to Buy Right Now
Pharmaceutical Technology
5 hours ago
Haya secures $65m in Series A funds to advance heart failure treatment
Motley Fool
16 hours ago
One of the Largest Teacher Pension Funds in the U.S. Sold Nvidia, Tesla, and Apple and Piled Into a Popular Pharmaceutical Stock Up 395% Over the Last 5 Years
Compare LLY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LLY Eli Lilly and Company - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.